Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
View Patent ↗The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen.
1. A purified peptide of 12-50 amino acid residues comprising an antigenic stratum corneum chymotryptic enzyme (SCCE) sequence of 12-50 amino acid residues;
wherein when the purified peptide is contacted with dendritic cells to generate peptide-loaded dendritic cells and the peptide-loaded dendritic cells are contacted with T cells, the peptide-loaded dendritic cells amplify CD4+ T cells (helper T cells) that recognize the SCCE sequence;
wherein the antigenic SCCE sequence is SEQ ID NO:15 (residues 1-23 of SCCE), SEQ ID NO:16 (residues 61-84), SEQ ID NO:17 (residues 143-160), or a fragment thereof that comprises at least 12 consecutive amino acid residues of SEQ ID NO:15, at least 12 consecutive amino acid residues of SEQ ID NO:16, or at least 12 consecutive amino acid residues of SEQ ID NO:17.
2. The purified peptide of claim 1 wherein when the purified peptide is contacted with dendritic cells to generate peptide-loaded dendritic cells and the peptide-loaded dendritic cells are contacted with T cells, the peptide-loaded dendritic cells amplify CD8+ T cells (cytotoxic T lymphocytes, CTL) that recognize the antigenic SCCE sequence.
3. The purified peptide of claim 1 wherein the peptide can be used with dendritic cells to activate CD4+ T cells from at least two donors with no HLA class II alleles in common.
4. The purified peptide of claim 2 wherein CD8+ T cells amplified with the peptide perform peptide-dependent lysis of at least two lines of target allogeneic cells pulsed with the peptide, wherein the two lines of target allogeneic cells are matched to the CD8+ T cells in different and non-overlapping HLA class I alleles.
5. The purified peptide of claim 1 wherein the peptide is 12-40 amino acid residues.
6. The purified peptide of claim 1 wherein the purified peptide comprises SEQ ID NO:15 (residues 1-23 of SEQ ID NO:1), SEQ ID NO:16 (residues 61-84 of SEQ ID NO:1), or SEQ ID NO:17 (residues 143-160 of SEQ ID NO:1).
7. The purified peptide of claim 1 wherein the peptide comprises an antigenic fragment of any one of SEQ ID NOS:15, 16, and 17.
8. A composition of matter comprising:
purified dendritic cells loaded ex vivo with a purified peptide of 12-50 amino acid residues comprising an antigenic SCCE sequence of 12-50 amino acid residues;
wherein when the purified peptide is contacted with dendritic cells to generate peptide-loaded dendritic cells and the peptide-loaded dendritic cells are contacted with T cells, the peptide-loaded dendritic cells amplify CD4+ T cells (helper T cells) that recognize the SCCE sequence;
wherein the antigenic SCCE sequence is SEQ ID NO:15 (residues 1-23 of SCCE), SEQ ID NO:16 (residues 61-84), SEQ ID NO:17 (residues 143-160), or a fragment thereof that comprises at least 12 consecutive amino acid residues of SEQ ID NO:15, at least 12 consecutive amino acid residues of SEQ ID NO:16, or at least 12 consecutive amino acid residues of SEQ ID NO:17.
9. The composition of claim 8 wherein when the purified peptide is contacted with dendritic cells to generate peptide-loaded dendritic cells and the peptide-loaded dendritic cells are contacted with T cells, the peptide-loaded dendritic cells amplify CD8+ T cells (cytotoxic T lymphocytes, CTL) that recognize the SCCE sequence.
10. The composition of claim 9 wherein the amplified CD8+ T cells kill autologous cancer cells expressing SCCE.
11. A composition of matter comprising:
purified dendritic cells loaded ex vivo with a purified peptide comprising an antigenic SCCE sequence of at least 12 amino acid residues;
wherein when the purified peptide is contacted with dendritic cells to generate peptide-loaded dendritic cells and the peptide-loaded dendritic cells are contacted with T cells, the peptide-loaded dendritic cells amplify CD4+ T cells (helper T cells) that recognize the SCCE sequence;
wherein the antigenic SCCE sequence is SEQ ID NO:15 (residues 1-23 of SCCE), SEQ ID NO:16 (residues 61-84), SEQ ID NO:17 (residues 143-160), or a fragment thereof that comprises at least 12 consecutive amino acid residues of SEQ ID NO:15, at least 12 consecutive amino acid residues of SEQ ID NO:16, or at least 12 consecutive amino acid residues of SEQ ID NO:17.
12. The composition of matter of claim 11 wherein the peptide can be used with dendritic cells to activate CD4+ T cells from at least two donors with no HLA class II alleles in common.
13. The composition of matter of claim 8 wherein the peptide can be used with dendritic cells to activate CD4+ T cells from at least two donors with no HLA class II alleles in common.
14. The purified peptide of claim 1 wherein the antigenic SCCE sequence is SEQ ID NO:15 or a fragment thereof.
15. The purified peptide of claim 1 wherein the antigenic SCCE sequence is SEQ ID NO:16 or a fragment thereof.
16. The purified peptide of claim 1 wherein the antigenic SCCE sequence is SEQ ID NO:17 or a fragment thereof.